These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30535947)

  • 21. [Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].
    Kojima K
    Rinsho Ketsueki; 2020; 61(9):1275-1280. PubMed ID: 33162526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal residual disease in chronic lymphocytic leukaemia.
    García Vela JA; García Marco JA
    Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
    Iovino L; Shadman M
    Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
    Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
    Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
    Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
    Front Oncol; 2019; 9():689. PubMed ID: 31555576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia.
    Molica S; Allsup D; Gianfelici V; Levato L; Aiello V; Bailey J; Polliack A
    Expert Opin Investig Drugs; 2021 Jun; 30(6):621-633. PubMed ID: 33929928
    [No Abstract]   [Full Text] [Related]  

  • 28. [Chemotherapy-free treatment of chronic lymphocytic leukemia?].
    Wendtner CM
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2104-6. PubMed ID: 24085367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge.
    Smolej L
    Curr Cancer Drug Targets; 2016; 16(8):701-709. PubMed ID: 27055577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
    Marini BL; Samanas L; Perissinotti AJ
    J Oncol Pharm Pract; 2017 Oct; 23(7):502-517. PubMed ID: 27357816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
    Daniel C; Mato AR
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
    Robak T; Blonski JZ; Robak P
    Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Rossi D; Gerber B; Stüssi G
    Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic lymphocytic leukemia therapy: new targeted therapies on the way.
    Vitale C; Burger JA
    Expert Opin Pharmacother; 2016 Jun; 17(8):1077-89. PubMed ID: 26988407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The future of chronic lymphocytic leukemia: potential directions from ASH 2017.
    Molica S
    Expert Rev Hematol; 2018 Jun; 11(6):481-486. PubMed ID: 29791237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world management of targeted therapies in chronic lymphocytic leukemia.
    Weis TM; Gutierrez J; Kabel CC; King AC; Daley RJ; Stump SE
    J Oncol Pharm Pract; 2022 Sep; 28(6):1411-1433. PubMed ID: 35350909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
    Cramer P; Langerbeins P; Eichhorst B; Hallek M
    Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRD-directed therapy in CLL: ready for prime time?
    Rhodes JM; Lopez CA; Barrientos JC
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):413-420. PubMed ID: 38066928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Treatment of Chronic Lymphocytic Leukemia.
    Jamroziak K; Puła B; Walewski J
    Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies].
    Gurbity Pálfi T; Fésüs V; Bödör C; Borbényi Z
    Orv Hetil; 2017 Oct; 158(41):1620-1629. PubMed ID: 29025288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.